Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The firm's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Follow-Up Questions
Scinai Immunotherapeutics Ltd (SCNI) 的本益比是多少？
Scinai Immunotherapeutics Ltd 的本益比是 0.2597
Scinai Immunotherapeutics Ltd 的 CEO 是誰？
Mr. Amir Reichman 是 Scinai Immunotherapeutics Ltd 的 Chief Executive Officer，自 2021 加入公司。
SCNI 股票的價格表現如何？
SCNI 的當前價格為 $1.51，在上個交易日 increased 了 3.37%。
Scinai Immunotherapeutics Ltd 的主要業務主題或行業是什麼？
Scinai Immunotherapeutics Ltd 屬於 Biotechnology 行業，該板塊是 Health Care
